Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 6/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MARS1 | P56192 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4935720 | 0.88 | HPGD (0.45) | CHRNA7MGLLCYP3A4HPGDCYP1A2 | |
| SCHEMBL4923151 | 0.85 | MDM2 (0.45) | MGLL | |
| SCHEMBL5163560 | 0.85 | MARS1 (0.46) | MARS1 | |
| SCHEMBL4931335 | 0.85 | MGLL (0.38) | CHRNA7MGLLSCN9ACYP3A4HPGD | |
| SCHEMBL4931192 | 0.84 | MGLL (0.45) | CHRNA7MGLLCYP3A4USP2CYP1A2 | |
| SCHEMBL4931713 | 0.83 | CHRNA7 (0.40) | CHRNA7MGLLCYP3A4USP2CYP1A2 | |
| SCHEMBL4931684 | 0.83 | KDM1A (0.43) | CHRNA7MGLLCYP3A4USP2SMN1; SMN2 | |
| SCHEMBL4931848 | 0.83 | CHRNA7 (0.46) | CHRNA7MGLLCYP3A4HPGDUSP2 | |
| SCHEMBL4926813 | 0.81 | VNN1 (0.39) | CHRNA7MGLLCYP3A4USP2CYP1A2 | |
| SCHEMBL4932048 | 0.81 | MGLL (0.38) | CHRNA7MGLLCYP3A4USP2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064682-A1 | Pyrazole Derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-13 | — | — | US | disclosed |
| CN-1980912-A | Pyrazole derivatives | DAIICHI SEIYAKU CO (JP) | 2007-06-13 | — | — | CN | disclosed |
| EP-1762568-A1 | PYRAZOLE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064682-A1 | Pyrazole Derivatives | NAT1, AR, CBR3 | CHRNA7 3075/4885MGLL 4785/4885SCN9A 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.